nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

11.10.2018 | short review

Aggressive variant and treatment-related neuroendocrine prostate cancer: two different terms for the same disease?

verfasst von: Igor Tsaur, Prof. Christian Thomas, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Summary

Previously assumed to be rare, the prevalence of aggressive variants of prostate cancer has increased rapidly. This histologically heterogeneous group of cancers, including different forms of the neuroendocrine carcinoma of the prostate, share a common clinical course associated with a poor response to androgen deprivation treatment and fatal prognosis. Currently, the most commonly used terms are aggressive variant of prostate cancer and treatment-related neuroendocrine prostate cancer. The best treatment of these tumors in clinical routine is still being debated. Here, we highlight the clinically most relevant aspects of this heterogeneous disease and summarize recommendations for clinical routine.

Vorheriger Artikel The microbiome of the prostate

Nächster Artikel Lutetium-PSMA therapy—a new therapeutic option in metastatic castration-resistant prostate cancer?

Mottet N, Bellmunt J, Briers E, et al. EAU – ESTRO – ESUR – SIOG guidelines on prostate cancer. EAU Annual Congress Copenhagen 2018. Arnhem: EAU Guidelines Office; 2018. ISBN 978-9492671028.

Tilki D, Schaeffer EM, Evans CP. Understanding mechanisms of resistance in metastatic castration-resistant prostate cancer: the role of the androgen receptor. Eur Urol Focus. 2016;2(5):499–505.CrossRefPubMed

Zaffuto E, Pompe R, Zanaty M, Bondarenko HD, Leyh-Bannurah SR, Moschini M, et al. Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis. Clin Genitourin Cancer. 2017;15(5):e793–e800.CrossRefPubMed

Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov. 2011;1(6):466–8.CrossRefPubMedPubMedCentral

Small EJ, Huang J, Youngren J, Sokolov A, Aggarwal RR, Thomas G, et al. Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). J Clin Oncol. 2015;33(15 suppl):5003.

Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32(1):65–71.CrossRefPubMed

Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018; https://doi.org/10.1200/JCO.2017.77.6880.CrossRefPubMedPubMedCentral

Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38:756–67.CrossRefPubMedPubMedCentral

Nadal R, Schweizer M, Kryvenko ON, et al. Small cell carcinoma of the prostate. Nat Rev Urol. 2014;11:213–9.CrossRefPubMedPubMedCentral

10.

Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(13):3621–30.CrossRefPubMedPubMedCentral

11.

Aparicio AM, Shen L, Tapia EL, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res. 2016;22(6):1520–30.CrossRefPubMed

12.

Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992;147(3 Pt 2):935–7.CrossRefPubMed

13.

Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20(14):3072–80.CrossRefPubMed

14.

Culine S, El Demery M, Lamy PJ, Iborra F, Avances C, Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol. 2007;178(3 Pt 1):844–8. discussion 8.CrossRefPubMed

15.

Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol. 2011;22(11):2476–81.CrossRefPubMed

16.

Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006;30(6):684–93.CrossRefPubMed

17.

de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015;21(4):795–807.CrossRefPubMedPubMedCentral

18.

Aparicio A, Xiao L, Tapia ELN, Hoang A, Ramesh N, Wu W, et al. The aggressive variant prostate carcinoma (AVPC) molecular signature (‑MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC). J Clin Oncol. 2017;35(15 suppl):5013.CrossRef

19.

Corn PG, Tu S‑M, Zurita AJ, Subudhi SK, Araujo JC, Kim J, et al. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2015;33(15 suppl):5010.

20.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, et al. Management of atients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73(2):178–211.CrossRefPubMed

Titel: Aggressive variant and treatment-related neuroendocrine prostate cancer: two different terms for the same disease?
verfasst von: Igor Tsaur
Prof. Christian Thomas, MD
Publikationsdatum: 11.10.2018
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-018-0442-9

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Lutetium-PSMA therapy—a new therapeutic option in metastatic castration-resistant prostate cancer?

Economic analysis of biomarker-based anti-EGFR therapies in metastatic colorectal cancer in the Austrian context

Educational no. 3: Cytogenetic analysis (CA)

Significance of genetic polymorphisms in hematological malignancies: implications of risk factors for prognosis and relapse

Cure in metastatic disease: how to manage and who is the right patient in colorectal cancer?

ASCO 2018: highlights in HER2-positive metastatic breast cancer